Events
Sysnav Healthcare at ISDS 2026
For years, clinical trials in achondroplasia have relied heavily on annual growth velocity as the primary
September 1, 2026
We provide the Syde® platform, a solution for motor function assessment in clinical studies, powered by:
Pharmaceutical
companies
Patient
associations
Researchers
and physicians
Sysnav Healthcare combines regulatory expertise, precision technology, operational excellence, and scientific rigor to deliver real-world digital endpoints that accurately capture patients’ functional changes.
• We developed SV95C (Stride Velocity 95th Centile, top ambulation speed), the first digital endpoint qualified by EMA¹.
• We have a strong track record of contributions to EMA and FDA-approved clinical trial protocols.
• Our DHT Syde® generates 3D reconstructions of patient movements with centimetric precision²’³ to deliver precise patient function outcomes.
• Our all-in-one solution seamlessly integrate with trial operations across all trial phases.
• We provide regulatory support, helping trials meet FDA and other authority requirements efficiently.
• We systematically assess the analytical and clinical validity of our endpoints⁴.
• Our strength lies in a deep bench of scientific and technical experts, trained at leading institutions, including Cambridge, MIT, Stanford, Ecole Polytechnique.
Schedule a meeting with our team to learn more.
For years, clinical trials in achondroplasia have relied heavily on annual growth velocity as the primary
In July 2023, the European Medicines Agency (EMA) granted qualification to SV95C (Stride Velocity 95th Centile)
How do you assess a patient too young to follow instructions? That’s the challenge our Program
By clicking on submit, you consent to being contacted by Sysnav about its products and services and you agree to the terms and conditions stated in the privacy policy.